
Pharmaceutical giant Pfizer Inc and German biotech firm BioNTech SE on Wednesday said they had signed a deal to supply Canada with an experimental coronavirus vaccine.
Deliveries of the BNT162 mRNA-based vaccine candidate are planned over the course of 2021, subject to clinical success and Health Canada approval, the two companies said in a statement. They did not reveal financial details.